KLOW Blend: Four Peptides for Inflammation and Repair
A single-vial 4-peptide blend combining GHK-Cu, KPV, BPC-157, and TB-500 — the most comprehensive of the popular research recovery blends.
What is KLOW Blend?
A single-vial blend combining GHK-Cu (skin/collagen remodeling), KPV (anti-inflammatory, gut and skin support), BPC-157 (soft-tissue and gut healing), and TB-500 (systemic tissue repair and angiogenesis) — the most comprehensive of the popular multi-peptide recovery blends, one injection covering skin, gut, and connective-tissue research angles at once.
Quick facts
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
Most commonly sold as an 80mg vial (50mg GHK-Cu, 10mg KPV, 10mg BPC-157, 10mg TB-500); reconstitute with 3.0mL bacteriostatic water for roughly 26.7mg/mL total blend concentration. Ratios vary by supplier. Run the numbers in the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| Joint, Gut & Skin Recovery | Bgrade | no trial of the 4-peptide combination; half its components are preclinical-only |
KLOW Blend Mechanism of Action
Four Mechanisms in One Vial
KLOW combines four peptides that individually target overlapping-but-distinct repair pathways: GHK-Cu upregulates collagen, elastin, and angiogenic growth-factor expression for skin/connective-tissue remodeling; KPV carries anti-inflammatory melanocortin signaling without pigmentation effects; BPC-157 shows gastroprotective and soft-tissue repair activity through nitric-oxide signaling and growth-factor modulation; TB-500 promotes cell migration and angiogenesis via actin-sequestering pathways. Combined, the blend targets skin, gut, and connective-tissue repair simultaneously.
Composition
KLOW is most commonly sold as an 80mg vial containing 50mg GHK-Cu, 10mg KPV, 10mg BPC-157, and 10mg TB-500 — GHK-Cu dominates the formulation by mass, with the other three peptides present at equal, smaller doses. Exact ratios vary by supplier, so always confirm the specific vial's composition before dosing.
KLOW Blend Dosage and Protocols
Dosing by GHK-Cu Content
Clinics commonly dose KLOW by its GHK-Cu content — roughly 1–2mg GHK-Cu equivalent per injection, which works out to about 16–32 units on a U-100 insulin syringe after standard reconstitution. Typical total-blend doses run 250–750mcg daily. Reconstitute the 80mg vial with 3.0mL bacteriostatic water for a concentration of about 26.7mg/mL total blend (vendor protocols range 1–3mL). Cycles commonly run 4–12 weeks.
KLOW Blend Side Effects and Safety
Combined Component Risk Profile
Because KLOW combines four separately-acting peptides, its side-effect profile reflects the union of each component's known/theoretical risks — mild injection-site irritation, and (from the BPC-157/TB-500 pairing) the standard soft-tissue-repair-peptide caution around active malignancy given their angiogenic and cell-migration-promoting mechanisms. No formal combined-product safety trial exists.
KLOW Blend Research Evidence
Individually Studied, Never Combined in a Trial
Each of KLOW's four components has its own body of preclinical and observational research individually. No clinical trial has ever tested the 4-peptide combination itself — the blend's rationale rests on combining individually-plausible mechanisms, not on trial data for the combination as a product.
Regulatory and Legal Status
KLOW is sold exclusively as a research-grade compound and is not approved for human consumption by the FDA or any equivalent regulatory body. Researchers and users should verify the legal status of KLOW and its individual component peptides in their jurisdiction prior to purchase or use.
KLOW Blend Stacking and Combinations
A Standalone All-in-One Blend
KLOW is designed as a comprehensive standalone recovery blend rather than a component of a larger stack — it already combines four peptides in one vial. Some researchers still pair it with GH secretagogue blends (e.g. CJC-1295 no-DAC + Ipamorelin) for broader systemic recovery support alongside KLOW's localized tissue-repair focus.
KLOW Blend Pharmacokinetics
No Unified PK Profile
KLOW's four components have distinct individual pharmacokinetic profiles and are not expected to share a single half-life — there is no published pharmacokinetic study of the combined blend as a product. Reconstituted KLOW should be refrigerated and used within the timeframe recommended by the specific vendor, consistent with standard peptide-blend handling practice.
Contraindications
- active malignancy
- pregnancy
Frequently asked questions
What is a typical KLOW Blend dose?
Published research protocols report 250–750 mcg total blend, daily. This is the range described in the literature, not a recommendation.
Is KLOW Blend backed by strong evidence?
KLOW Blend carries a REGEN research grade of C. REGEN Research Tier B — observational human data (cohort / case studies).
How is KLOW Blend administered?
Routes reported in the literature: subcutaneous.
Who should avoid KLOW Blend?
Contraindications noted in the literature include active malignancy, pregnancy.